49 related articles for article (PubMed ID: 38427922)
1. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data.
Lippenszky L; Mittendorf KF; Kiss Z; LeNoue-Newton ML; Napan-Molina P; Rahman P; Ye C; Laczi B; Csernai E; Jain NM; Holt ME; Maxwell CN; Ball M; Ma Y; Mitchell MB; Johnson DB; Smith DS; Park BH; Micheel CM; Fabbri D; Wolber J; Osterman TJ
JCO Clin Cancer Inform; 2024 Feb; 8():e2300207. PubMed ID: 38427922
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
7. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
8. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy.
Dionese M; Basso U; Pierantoni F; Lai E; Cavasin N; Erbetta E; Jubran S; Bonomi G; Bimbatti D; Maruzzo M
Future Sci OA; 2023 Aug; 9(7):FSO878. PubMed ID: 37485441
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
Goodman RS; Jung S; Balko JM; Johnson DB
Immunol Rev; 2023 Sep; 318(1):157-166. PubMed ID: 37470280
[TBL] [Abstract][Full Text] [Related]
12. Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning.
Gong L; Gong J; Sun X; Yu L; Liao B; Chen X; Li YS
Front Immunol; 2023; 14():1138489. PubMed ID: 37457722
[TBL] [Abstract][Full Text] [Related]
13. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F; Azuma K; Nakahara Y; Saito H; Matsuo N; Tagami T; Kouro T; Igarashi Y; Tokito T; Kato T; Kondo T; Murakami S; Usui R; Himuro H; Horaguchi S; Tsuji K; Murotani K; Ban T; Tamura T; Miyagi Y; Sasada T
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433717
[TBL] [Abstract][Full Text] [Related]
14. Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.
He LN; Li H; Du W; Fu S; Luo L; Chen T; Zhang X; Chen C; Jiang Y; Wang Y; Wang Y; Yu H; Zhou Y; Lin Z; Zhao Y; Huang Y; Zhao H; Fang W; Yang Y; Zhang L; Hong S
iScience; 2023 Jul; 26(7):107058. PubMed ID: 37416452
[TBL] [Abstract][Full Text] [Related]
15. Accelerated curation of checkpoint inhibitor-induced colitis cases from electronic health records.
Rahman P; Ye C; Mittendorf KF; Lenoue-Newton M; Micheel C; Wolber J; Osterman T; Fabbri D
JAMIA Open; 2023 Apr; 6(1):ooad017. PubMed ID: 37012912
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
